Table 2.
Effect of Alpha-Mangostin on Liver Function Test and Renal Function Test of Rats at the End of 11 Weeks
| Variable | Control (n=6) Mean ± SD |
Control + AM200 (n=6) Mean ± SD |
HF/HG/STZ (n=6) Mean ± SD |
HF/HG/STZ + Metformin (n=6) Mean ± SD |
HF/HG/STZ + AM100 (n=6) Mean ± SD |
HF/HG/STZ + AM200 (n=6) Mean ± SD |
|---|---|---|---|---|---|---|
| ALT (mg/dL) | 15.17 ± 1.52 | 25.79 ± 6.30 | 75.17 ± 8.36* | 36.29 ± 7.20** | 49.58 ± 9.26# | 37.27 ± 5.27## |
| AST (mg/dL) | 32.55 ± 4.21 | 40.02 ± 2.4 | 74.56 ± 6.75* | 55.16 ± 8.23** | 54.06 ± 3.92# | 53.70 ± 5.54## |
| BUN (mg/dL) | 22.63 ± 2.89 | 25.91 ± 4.61 | 37.28 ± 13.48* | 17.01 ± 1.69** | 16.65 ± 6.14# | 22.07 ± 5.31## |
| Uric acid (mg/dL) | 1.7 ± 0.13 | 1.51 ± 0.28 | 6.59 ± 0.09* | 2.32 ± 1.9 | 4.43 ± 1.8 | 3.41 ± 2.13 |
Notes: *p < 0.05 HF/HG/STZ vs control and control-treated with alpha-mangostin. **p < 0.05 HF/HG/STZ vs HF/HG/STZ + Metformin. #p < 0.05 HF/HG/STZ vs HF/HG/STZ + AM 100. ##p < 0.05 HF/HG/STZ vs HF/HG/STZ + AM 200. Results are represented as mean ± SD and were analyzed using one-way ANOVA followed by Tukey’s post-hoc analysis. Values are considered significantly different at p < 0.05.